---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000016"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T09:30:11.471552+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EU grants conditional marketing authorization for Travere's FILSPARI in IgA nephropathy

## Summary
- European Commission approved FILSPARI (sparsentan) for adults with primary IgAN with urine protein excretion ≥1.0 g/day or UPCR ≥0.75 g/g.
- Approval covers all EU member states plus Iceland, Liechtenstein, Norway; follows CHMP positive opinion in February 2024.
- Decision based on pivotal Phase 3 PROTECT Study results; FILSPARI already has accelerated approval in the US.
- CSL Vifor holds exclusive commercialization rights in Europe, Australia, New Zealand; expects launch in first European markets in H2 2024.

## SEC filing metadata
- accession: 0001438533-24-000016
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000016/0001438533-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000016/tvtx-20240424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000016
- JSON: https://secwatch.observer/filing/0001438533-24-000016.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.